If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped?

The burden is on the drug, not on the patient's body, to prove it is doing more good than harm.

Digoxin toxicity is a clinical diagnosis first, not a lab value. Before you stop the drug, you document the findings that point to toxicity, and you do it in writing, because that record is what protects the patient when the system tries to call it something else.

The classic triad is gastrointestinal, cardiac, and neurologic. Nausea, vomiting, anorexia, and abdominal pain are the gut signals, but they are nonspecific and easy to dismiss as a stomach bug. The cardiac findings matter more: bradycardia, especially a rate under 60, new PR prolongation on the ECG, ST segment depression that looks like a scooped "reverse tick," and any new arrhythmia, particularly atrial fibrillation with a slow ventricular response, or the more ominous bidirectional ventricular tachycardia, which is nearly pathognomonic for digoxin. The neurologic signs are the ones most often missed: confusion, disorientation, visual disturbances like yellow-green halos around lights, and in older adults, just a vague "off" feeling that gets blamed on age.

You also document the context that makes toxicity more likely: renal function, because digoxin is cleared by the kidneys and a creatinine bump can double the drug level; potassium, because hypokalemia potentiates digoxin's effect even at a "therapeutic" serum level; magnesium and calcium, because imbalances amplify the arrhythmia risk; and any interacting drugs, like amiodarone, verapamil, or certain diuretics that raise the digoxin concentration. A serum digoxin level is useful but not decisive. A level in the "therapeutic" range does not rule out toxicity in a patient with hypokalemia or renal failure, and a high level in an asymptomatic patient does not automatically mean you stop the drug if the clinical picture is clean.

Now, the deeper question you are really asking, and the one the institution will not say plainly, is whether the drug should have been started at all. Digoxin is a narrow-therapeutic-index drug, meaning the distance between a helpful dose and a harmful one is small. It is a plant toxin, digitoxin from foxglove, refined into a pill. It does not fix the underlying heart failure; it pushes the failing heart harder while slowing the electrical system. The trials that support it are old, small, and mostly industry-adjacent. The modern evidence for mortality benefit is thin, and the evidence for harm, especially in women and in the elderly, is real. The ALLHAT trial and subsequent analyses showed digoxin did not reduce death, and it increased the risk of hospitalization for heart failure in women compared to men. The drug trades one set of symptoms for another set of risks, and the toxicity you are documenting is not an accident. It is the predictable end of a drug that has no margin.

So when you suspect toxicity, you do not wait for the level to confirm it. You document the clinical findings, you check the electrolytes and the renal function, you get the ECG, and you stop the drug. Then you ask the harder question: why was this patient on digoxin in the first place, and what safer alternatives, like beta-blockers or ACE inhibitors with real mortality data, were not tried first? The answer is usually that digoxin is cheap, familiar, and easy to prescribe, which is a reason for the doctor, not for the patient. The confidence here is high. The mechanism is clear, the clinical signs are well described, and the evidence that digoxin is overused and under-monitored is solid. The evidence that it helps is weaker than the reflex to prescribe it.